article thumbnail

AAFP Represents Members During 2025 Legislative Session

Alabama Academy of Family Physicians

These funds could be utilized for various purposes, including direct care, operational expenses, and facility maintenance or upgrades. Pharmacy benefits managers would be further required to pass on 100 percent of rebates received from drug manufacturers to the health benefit plans for which they provide services.

Insurance 130
article thumbnail

Developments in State Prescription Drug Price Transparency Laws

FDA Law Blog

Schlanger — While federal efforts to address prescription drug prices are debated, states have continued to pursue their own measures that require drug manufacturers and other entities in the drug supply chain to disclose information about pricing. By Serra J. See our previous coverage of such state laws here , here and here.)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ep. 68: Hidden risks of prescribing GLP-1 drugs with Ericka L. Adler, J.D., of Roetzel & Andress

Physician's Practice

Insurance Denials and Prior Authorizations (00:11:26)** Challenges with insurance coverage, prior authorizations, and evolving insurer policies for GLP-1 prescriptions.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

Association of Sensory and Cognitive Impairment With Healthcare Utilization and Cost in Older Adults. Including more hospital utilization or healthcare utilization, maybe cognitive impairment issues. My own work focuses on hospitalization and health utilization over time. Five big manufacturers. Is that right?

IT 102
article thumbnail

Key Bills in the 2025 Legislative Session AAFP is Watching Closely

Alabama Academy of Family Physicians

These funds could be utilized for various purposes, including direct care, operational expenses, and facility maintenance or upgrades. These funds could be utilized for various purposes, including direct care, operational expenses, and facility maintenance or upgrades.

Insurance 130
article thumbnail

Drug Pricing Reform Gathers Steam (Part 2)

FDA Law Blog

PART 1: MAXIMUM FAIR PRICE PAYMENT LIMITATION UNDER MEDICARE PARTS B AND D AND THE COMMERCIAL INSURANCE MARKET. The MFP would be established through negotiations between HHS and the manufacturer and would incorporate foreign pricing benchmarks, as further described below. The four parts of Subtitle E are summarized in turn below.